News from BiBBInstruments AB

Earlier this week BiBBInstruments AB announced a disappointing but predictable result of the TO1 subscription rate. With a very modest 18,7% subscription rate, BiBBInstruments AB receives 1,7 MSEK before costs.

Like most shareholders, LSIF did not utilize our TO1, because we need to act on market terms, and with a share price in the subscription period far below the subscription price of 3,25 SEK, we could not participate.
At LSIF, we want to emphasize, that we still have full confidence in our investment in BiBBInstruments AB, and only the poor design of the warrant made it impossible for us to support in this round.

2 days ago, BiBBInstruments AB provided a positive announcement stating that the company has signed a distribution agreement with TaeWoong Medical USA only 40 days after signing a LOI, which is encouraging. Jointly, the 2 companies are now doing a targeted launch of EndoDrill in the US in 2025 and a broader launch in 2026.

At LSIF, we view TaeWoong Medical USA as a very good partner for BiBBInstruments AB, and we look forward to follow this collaboration.

Link to press release here